Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections

A method of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically-effective amount of a compound having the general formula (I):

• wherein
• m is an integer between 0 and 2,
• n is equal to 0 or 1,
• is equal to 0 or 1,
• p is an integer between 0 and 2,
• p′ is an integer between 0 and 2,
• either the double line represents a single bond and
• X is selected from the group consisting of an oxygen atom, CH2, NH, N—R5 and —NCO—R5, wherein R5 represents a linear, branched and/or cyclic, saturated or unsaturated, hydrocarbon-based radical, optionally substituted, optionally comprising one or several heteroatoms and/or one or more groups containing one or more heteroatoms,
• and Y represents a methylene group, a carbonyl group, a thiocarbonyl group or a C═N—R9 group wherein R9 represents a hydrogen atom or an alkyl or aryl group,
• or the double line represents a double bond and X represents a nitrogen atom and Y represents a methine group,
• Z represents a covalent bond, a methylene group, a sulfonyl group, an amide group, an ester group, an ether group or a carbonyl group, provided that Z does not represent a carbonyl group when p is equal to 0,
• W represents a nitrogen atom or a C—R10 group wherein R10 represents a hydrogen atom or a linear, branched and/or cyclic, saturated or unsaturated, hydrocarbon-based radical, optionally substituted, optionally comprising one or several heteroatoms and/or one or more groups containing one or more heteroatoms,
• R1 is selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, a primary amine group, a linear or branched and/or cyclic saturated or unsaturated carbon-based radical, optionally aromatic, optionally substituted, optionally comprising one or several heteroatoms and/or one or more groups containing one or more heteroatoms, a —O—R6, —NH—R6 or —NH—CO—R6 group wherein R6 represents a linear, branched and/or cyclic, saturated or unsaturated, hydrocarbon-based radical, optionally substituted, optionally comprising one or several heteroatoms and/or one or more groups containing one or more heteroatoms, and an —NR—R5 group wherein R7 and R8, which may be identical or different, each represent a linear, branched and/or cyclic, saturated or unsaturated, hydrocarbon-based radical, optionally substituted, optionally comprising one or several heteroatoms and/or one or more groups containing one or more heteroatoms,
• and R2 is selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, a sulfonic acid group, a primary amine group, and a linear, branched and/or cyclic, saturated or unsaturated, carbon-based radical, optionally substituted, optionally aromatic, optionally comprising one or several heteroatoms and/or one or more groups containing one or more heteroatoms,
• or one of the pharmaceutically acceptable salts thereof.